In a recent study, Goricar et al. 59 has reported that detection of serum BIRC5 levels before and during chemotherapy could serve as a biomarker for predicting malignant mesothelioma treatment response in humans. This evidence concerns the gene BIRC5 and malignant mesothelioma.